A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial Carcinomas

Keyphrases

• Biopsy Specimen 20%
• Bladder Cancer Cell Lines 40%
• Cancer Cells 20%
• Cell Proliferation 20%
• Colony Formation Assay 20%
• Disease Progression 20%
• Downstream Effectors 20%
• Effector Function 20%
• Ether 20%
• Expression Level 20%
• Family Members 40%
• Head-and-neck Cancer 20%
• High-grade Urothelial Carcinoma 20%
• Inhibition Profiles 20%
• Inhibitor of Apoptosis Proteins 20%
• Integration Site 20%
• Invasive Urothelial Carcinoma 40%
• Kinase Inhibition 20%
• Leukemia/Lymphoma 20%
• Molecular Targets 20%
• Moloney murine Leukemia Virus 20%
• Multiple Cancers 20%
• Multiple Myeloma 20%
• Oral Bioavailability 20%
• Overexpression 20%
• Patient Tumor 20%
• Pharmacodynamic Biomarker 20%
• Phase Progression 20%
• PIM Kinase 100%
• PIM-1 20%
• PIM2 20%
• PIM3 20%
• Poor Prognosis 20%
• Positive Regulator 20%
• Potential Treatments 100%
• Prostate 20%
• Proto-oncogene 20%
• Resection Specimen 20%
• Serine/threonine Kinase 20%
• Signaling Pathway 20%
• Small Molecule Inhibitors 100%
• Surgical Biopsy 20%
• Surgical Resection 20%
• Targets for Therapy 20%
• Tumor Growth 20%
• Urothelial Carcinoma 100%
• Viral Integration 20%
• Xenograft Studies 20%

Medicine and Dentistry

• Aciclovir 20%
• Bioavailability 20%
• Biological Marker 20%
• Biopsy Technique 20%
• Bladder Cancer Cell Line 40%
• Cancer Cell 20%
• Cell Cycle 20%
• Cell Proliferation 20%
• Colony Formation 20%
• Cytochrome P450 20%
• Diethyl Ether 20%
• Disease Exacerbation 20%
• Head and Neck Cancer 20%
• Kinase 100%
• Leukemia 20%
• Multiple Myeloma 20%
• Oral 20%
• Pharmacodynamics 20%
• Phosphotransferase 20%
• Phosphotransferase Inhibitor 20%
• Programmed Cell Death 20%
• Protein Serine Threonine Kinase 20%
• Proteus Syndrome 20%
• Proto Oncogene 20%
• S Phase 20%
• Signal Transduction 20%
• Transitional Cell Carcinoma 100%
• Tumor 20%
• Tumor Progression 20%
• Xenograft 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Aciclovir 20%
• Bioavailability 20%
• Biological Marker 20%
• Bladder Cancer 40%
• Cytochrome P450 20%
• Disease Exacerbation 20%
• Head and Neck Cancer 20%
• Leukemia 20%
• Malignant Neoplasm 20%
• Molecular Target 20%
• Moloney Murine Leukemia Virus 20%
• Multiple Cancer 20%
• Multiple Myeloma 20%
• Pharmacodynamics 20%
• Phosphotransferase 20%
• Phosphotransferase Inhibitor 20%
• Protein Serine Threonine Kinase 20%
• Transitional Cell Carcinoma 100%
• Tumor Growth 20%